Orchard Therapeutics Plc
(NASDAQ : ORTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.09%145.210.7%$864.96m
PFEPfizer Inc. 2.06%38.200.9%$794.52m
MRKMerck & Co., Inc. 0.85%79.880.7%$633.76m
ABBVAbbVie, Inc. 0.13%84.421.9%$605.70m
BMYBristol-Myers Squibb Co. -1.05%60.121.0%$597.45m
LLYEli Lilly & Co. 0.48%142.331.1%$480.95m
AZNAstraZeneca Plc 0.08%52.001.2%$210.07m
GSKGlaxoSmithKline Plc 0.60%35.300.2%$147.41m
NVSNovartis AG 0.07%84.470.2%$138.31m
NVONovo Nordisk A/S -0.20%70.740.1%$71.09m
RGENRepligen Corp. -0.15%176.257.1%$66.58m
RPRXRoyalty Pharma Plc -0.51%39.010.2%$65.42m
SNYSanofi 0.82%49.330.2%$48.25m
AMAGAMAG Pharmaceuticals, Inc. 0.07%13.6722.1%$45.61m
OPKOPKO Health, Inc. 0.70%4.3011.2%$41.80m

Company Profile

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.